Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes
By HospiMedica International staff writers Posted on 05 Mar 2021 |
Image: Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes (Photo courtesy of Purdue University/Chris Adam)
An all new technology can detect COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests.
IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.
Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.
"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.
Related Links:
IdentifySensors Biologics
Purdue Research Foundation
IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.
Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.
"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.
Related Links:
IdentifySensors Biologics
Purdue Research Foundation
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans